Search
Melphalan flufenamide
go.drugbank.com/drugs/DB16627ApprovedWithdrawnIt has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and [dexamethasone … [A230143,L32173] Melphalan flufenamide was granted FDA approval on 26 February 2021.[L32173].
Astemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnAstemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. … It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Norepinephrine
go.drugbank.com/drugs/DB00368ApprovedInvestigationalIt is also found in plants and is used pharmacologically as a sympathomimetic. … Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus.
Products: N-EPI, Norepinephrine Bitartrate In Sodium ChlorideKetamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedIt was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332] … Ketamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories.
Categories: N-Methylaspartate, agonists, N-Methylaspartate, antagonists & inhibitorsProducts: Ketamin G.L. 10 mg/ml - Injektions-/Infusionslösung in Ampullen, Ketamin G.L. 50 mg/ml - Injektions-/Infusionslösung in AmpullenRopeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigational[A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials. … Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for
Products: BESREMi PenDamoctocog alfa pegol
go.drugbank.com/drugs/DB14700ApprovedInvestigationalIn order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized. … [L4576,A38909] This product has been engineered by Bayer[L4576] and a biological license application has been filed with the FDA in August 2017 and FDA approved in August 2018.[F1609]
Gemtuzumab ozogamicin
go.drugbank.com/drugs/DB00056ApprovedInvestigationalin combination with chemotherapy or on its own [L941]. … The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML).
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently
Beractant
go.drugbank.com/drugs/DB06761ApprovedAdministration of lung surfactant remains the cornerstone of therapy in this condition that is currently the leading cause of death in preterm infants. … It is suspended in 0.9% sodium chloride solution, and heat-sterilized.
Ethylhexyl methoxycrylene
go.drugbank.com/drugs/DB11226ApprovedIt currently enjoys regional approvals in Canada, the EU, and the US [L2847]. … It is used as a solvent for crystalline UV filters and is easily emulsified and suitable for use in various lotions, creams, sprays, sticks, and gel formulations [F104].